Juvenile idiopathic arthritis (JIA) is an umbrella term for arthritis of unknown origin, lasting
for> 6 weeks with onset before 16 years of age. JIA is the most common chronic …

Signature Cytokines and Immune-Mediated Inflammatory Diseases The ability to block
specific cytokine pathways has revealed pathophysiological differences among autoimmune …

Objective To provide updated guidelines for pharmacologic management of juvenile
idiopathic arthritis (JIA), focusing on treatment of oligoarthritis, temporomandibular joint …

The emergent outbreak of coronavirus disease 2019 (COVID-19) has caused a global
pandemic. Acute respiratory distress syndrome (ARDS) and multiorgan dysfunction are …

Most rheumatic and musculoskeletal diseases (RMDs) can be placed along a spectrum of
disorders, with autoinflammatory diseases (including monogenic systemic autoinflammatory …

Background Experimental and clinical data suggest that reducing inflammation without
affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory …

Background Tofacitinib is an oral Janus kinase inhibitor. This trial assessed the efficacy and
safety of tofacitinib versus placebo in patients with polyarticular course juvenile idiopathic …

Inflammatory pathways drive atherogenesis and link conventional risk factors to
atherosclerosis and its complications. One inflammatory mediator has come to the fore as a …

Objective To develop criteria for the classification of macrophage activation syndrome (MAS)
in patients with systemic juvenile idiopathic arthritis (JIA). Methods A multistep process …

Recent therapeutic advances in juvenile idiopathic arthritis (JIA) have made remission an
achievable goal for most patients. Reaching this target leads to improved outcomes. The …